Greatest EGFR Prevalence in Women with Adenocarcinoma with No Smoking History

Share this content:

the Cancer Therapy Advisor take:

Women diagnosed with adenocarcinoma who never smoked demonstrated the greatest prevalence of epidermal growth factor receptor (EGFR) mutations, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.

The study included an initial dataset of 4,200 patients. In total, 4,196 of these participants were eligible—431 of which had EGFR mutations.

Results showed women  had significantly greater (P <0.0001) odds of EGFR mutations compared to males (OR: 1.85; 95% C: 1.48, 2.32).

A similar trend was observed for never-smokers versus smokers (OR, 3.64; 95% CI: 2.91, 4.56), and patients with adenocarcinoma versus other histologic subtypes (OR, 2.94; 95% CI: 2.17, 4.08).

Furthermore, EGFR tyrosine kinase inhibitors (TKIs) in EGFR mutation–positive non-small cell lung cancer (NSCLC) and combination chemotherapy in EGFR mutation–negative NSCLC were determined to be the most commonly prescribed first-line systemic treatments (56.6% and 78.5%, respectively).

The Rising Incidence of Lung Cancer in Non-Smoking Women: A Disturbing Trend
Women diagnosed with adenocarcinoma who never smoked demonstrated the greatest prevalence of epidermal growth factor receptor (EGFR) mutations.
↵* Corresponding Author: W. Schuette, Hospital Martha-Maria, Roentgenstr. 1, Halle-Dölau, 06120 Halle, Germany. Phone: 49-345-559-1440; Fax: 49-345-680-0376; E-mail: Wolfgang.Schuette{at}Martha-Maria.de W. Schuette and P. Schirmacher contributed equally to this article. Introduction: EGFR mutations confer sensitivity to EGFR tyrosine kinase inhibitors (TKI) in advanced non-small cell lung cancer (NSCLC).
READ FULL ARTICLE From cebp.aacrjournals.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters